| abstract |
Methods and compositions for cancer therapy using mutant LIGHT molecules with increased affinity for receptors. Disclosed are methods and compositions for targeting to tumor cells using embodiments of LIGHT proteins linked, fused or conjugated to targeting agents. These compositions bind to both human and mouse receptors with sufficient affinity to conduct preclinical and clinical trials and with increased affinity compared to wild-type human LIGHT protein. Targeting LIGHT of embodiments to tumor cells reduces tumor growth and metastasis. [Selection] Figure 30 |